OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $17.9450 +0.14 (+0.79 %) (As of 09/20/2018 02:46 PM ET)Previous Close$17.8050Today's Range$17.90 - $17.9952-Week Range$12.34 - $17.90Volume140,237 shsAverage Volume140,892 shsMarket Capitalization$34.65 billionP/E Ratio22.15Dividend Yield1.33%Beta0.37 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. The company has a collaborative and license agreement with Proteostasis Therapeutics, Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. Receive ALPMY News and Ratings via Email Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolOTCMKTS:ALPMY CUSIPN/A Webwww.astellas.com Phone813-3244-3000 Debt Debt-to-Equity Ratio0.04 Current Ratio1.93 Quick Ratio1.59 Price-To-Earnings Trailing P/E Ratio22.15 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.00 billion Price / Sales2.96 Cash Flow$1.0427 per share Price / Cash17.21 Book Value$5.52 per share Price / Book3.25 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$1.48 billion Net Margins13.49% Return on Equity13.46% Return on Assets9.37% Miscellaneous Employees16,617 Outstanding Shares1,980,000,000Market Cap$34.65 billion ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions What is ASTELLAS PHARMA/ADR's stock symbol? ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY." When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work? Shares of ASTELLAS PHARMA/ADR split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split. How were ASTELLAS PHARMA/ADR's earnings last quarter? ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) announced its earnings results on Friday, July, 27th. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $3.02 billion for the quarter. ASTELLAS PHARMA/ADR had a net margin of 13.49% and a return on equity of 13.46%. View ASTELLAS PHARMA/ADR's Earnings History. When is ASTELLAS PHARMA/ADR's next earnings date? ASTELLAS PHARMA/ADR is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for ASTELLAS PHARMA/ADR. What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ASTELLAS PHARMA/ADR. Who are some of ASTELLAS PHARMA/ADR's key competitors? Some companies that are related to ASTELLAS PHARMA/ADR include Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bayer (BAYRY), Allergan (AGN), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TKPYY). Who are ASTELLAS PHARMA/ADR's key executives? ASTELLAS PHARMA/ADR's management team includes the folowing people: Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 58)Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Corp. Exec.Ms. Linda Friedman J.D., Gen. Counsel & VPMr. Jeffrey A. Winton, Chief Communications Officer and Sr. VP of Corp. Affairs (Age 60) Has ASTELLAS PHARMA/ADR been receiving favorable news coverage? News stories about ALPMY stock have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ASTELLAS PHARMA/ADR earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave headlines about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for ASTELLAS PHARMA/ADR. How do I buy shares of ASTELLAS PHARMA/ADR? Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ASTELLAS PHARMA/ADR's stock price today? One share of ALPMY stock can currently be purchased for approximately $17.97. How big of a company is ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR has a market capitalization of $34.65 billion and generates $12.00 billion in revenue each year. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe. How can I contact ASTELLAS PHARMA/ADR? ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000. MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 137 (Vote Outperform)Underperform Votes: 85 (Vote Underperform)Total Votes: 222MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Equity (ROE)?